Medical treatment

Trends in Differential Diagnosis, Pathogenesis, and Medical Treatment


Supplier’s declaration

This continuing medical education activity is provided by

Statement of support

This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.

activity Descrition

Thyroid eye disease (TED) is a multifactorial autoimmune disease with a wide range of signs and symptoms. It is often misdiagnosed, due to both the heterogeneous clinical presentation and a failure to understand the relationship between PDD and hyperthyroidism. Misdiagnosis can put patients at increased risk of complications; however, a differential diagnosis can be obtained using imaging, and early diagnosis and treatment can limit disfigurement and reduce vision loss. Ophthalmologists, oculoplastic surgeons, ophthalmic and reconstructive plastic surgeons, neuro-ophthalmologists, and endocrinologists should be aware of the conventional and new therapies available for the treatment of patients with ASD and know how to apply this information in practice. As new information about TED continues to be released and presented, there is a need for education that addresses the range of its management.
This first of two TED360 Forum eMonographs aims to provide healthcare professionals with guidance on the appropriate use of therapies and strategies to provide individualized care to patients with ASD. In this eMonograph, expert professors examine trends in differential diagnosis, pathogenesis, and medical treatment in the management of ASD. Additionally, case challenges will demonstrate the application of the presented material in practice.

Target audience

The target audience for this activity is oculoplastic surgeons, ophthalmic plastic and reconstructive surgeons, neuro-ophthalmologists, endocrinologists, ophthalmologists and other healthcare professionals involved in the care of patients with ASD.

Learning objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the etiology, pathogenesis, and risk factors of PDD to better understand why early diagnosis can improve patient outcomes.
  • To review current guidelines and best practices that can improve the diagnosis of ASD so that early treatment can be initiated.
  • To assess the safety and efficacy of current medical treatments that may improve the management of patients with ASD.
  • To assess the benefit/risk profile of insulin-like growth factor receptor 1 (IGF-1R) therapy and how it can be incorporated into practice, safely and effectively.
  • Review case presentations, clinical outcomes, and management solutions that can improve overall outcomes for patients with ASD.

Course President

Raymond S. Douglas, MD, Ph.D.
Professor of Surgery
Division of Ophthalmology
Director, Orbital and Thyroid Eye Diseases Program
Cedars-Sinai Medical Center
Los Angeles, CA


Christian Nasr, MD, FACP, FACE
Medical Director – Thyroid Center
Institute of Endocrinology and Metabolism
Cleveland Clinic
Cleveland, Ohio

Terry J. Smith, MD
Frederick GL Huetwell Professor
Ophthalmology and visual sciences
Professor of internal medicine
University of Michigan School of Medicine
Ann Arbor, Michigan

Prem S. Subramanian, MD, Ph.D.
Professor of Ophthalmology, Neurology and Neurosurgery
University of Colorado School of Medicine
Vice President for Academic Affairs
Head of Division, Neuro-ophthalmology
University of Colorado Sue Anschutz-Rodgers Eye Center
Aurora, CO

Sara Tullis Wester, MD, FACS
Professor of Clinical Ophthalmology
Oculofacial plastic and reconstructive surgery
Orbital surgery and oncology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, Florida

medical writer

Valerie Zimmerman, PhD


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit designation

Vindico Medical Education designates this durable material for maximum 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the assessment component, enables the learner to meet the lifelong learning and self-assessment requirements of the Continuing Certification Program. American Board of Ophthalmology. It is the responsibility of the CME activity provider to submit learner completion information to ACCME for the purpose of granting credit.

If successful, learners who register by providing their ABO ID and date of birth (MM/DD) will earn Continuing Certification Credits equal to the number of CME Credits claimed for the activity.

This durable material is approved for 1 year from the original publication date, June 30, 2022, until June 29, 2023.

How to participate in this activity and get a CME credit

To participate in this CME activity, you must read the objectives, answer the survey and pretest questions, view the content, and complete the posttest and assessment. Provide only one (1) correct answer for each question. A satisfactory score is defined as a correct answer to 7 of the 10 post-test questions. Upon receipt of the completed documents, if a satisfactory post-test score is obtained, Vindico Medical Education will issue a AMA PRA Category 1 Credit(s)™ certificate.


Vindico Medical Education adheres to the ACCME Standards of Integrity and Independence for Accredited Continuing Education. Anyone in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, is required to disclose all relevant financial relationships with nonqualifying entities (business interests). All relevant conflicts of interest have been mitigated before the start of the activity.

The course director and faculty report the following relevant financial relationships

Raymond S. Douglas, MD, Ph.D.
Consultant: Horizon, Viridian Therapeutics

Christian Nasr, MD, FACP, FACE
Consultant: Horizon

Terry J. Smith, MD
Consultant: Horizon, Viridian Therapeutics

Prem S. Subramanian, MD, Ph.D.
Consultant: Horizon, Viridian Therapeutics
Independent Research Contractor: Horizon

Sara Tullis Wester, MD, FACS
Advise: Horizon

The medical writer reports the following relevant financial relationships

Valerie Zimmerman, PhD
No relevant financial relationship to disclose.

Based on presentations by Drs. Douglas, Nasr, Smith, Subramanian, and Wester at the CME Certified Live Virtual Symposium on March 26, 2022. The monograph has been approved by each of the faculties individually as an accurate representation of their presentations.

The reviewer reports the following relevant financial relationships

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationship to disclose.

Vindico Medical Education staff report the following relevant financial relationships

No relevant financial relationship to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Experimental Use

The public is advised that this continuing medical education activity may contain references to unlabeled uses of products approved by the United States Food and Drug Administration (FDA) or products not approved by the FDA for use in the United States. -United. Faculty members have been informed of their obligation to disclose such use. All activity participants will be notified if any speakers/authors intend to discuss non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Phone: 856-994-9400; Fax: 856-384-6680. Printed in USA. © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. Material presented at or in any of Vindico Medical Education’s continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorses or recommends any techniques, commercial products or manufacturers. Professors/authors may discuss the use of materials and/or products that have not yet been approved by the United States Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or using any product.

Questions about the CME?

Contact us at [email protected]